Peptide News Digest

TRUTAKNA $425K/Year Commercial Launch, Vertex Povetacicept PDUFA Nov 30, PCAC 4 Days Out

Vera TRUTAKNA launch details ($425K/year, 82 reps); Vertex povetacicept PDUFA Nov 30 derisked after Vera and Novartis IgAN approvals; PCAC 4 days out.

3 stories · Covering industry, regulatory

Editor's Note

Sunday's digest reads through the IgA nephropathy competitive shakeout that a compressed ten-day window produced. Vera Therapeutics set commercial-launch parameters for TRUTAKNA (atacicept-vymj) at a $425,000 per year list price with 82 sales representatives deployed and in-channel pharmacy availability within three to four weeks of the July 7 FDA accelerated approval; ORIGIN 3 confirmatory eGFR data anticipated in Q3 2026 will determine whether the accelerated approval converts to traditional approval. Vertex Pharmaceuticals' povetacicept, another BAFF/APRIL-blocking fusion protein designed to compete with TRUTAKNA on the same mechanism target, received FDA BLA acceptance with a November 30, 2026 PDUFA date; BioSpace analysis characterizes the program as derisked following both the Vera and Novartis approvals, expecting educational and access spillover from the competitor launches to accelerate povetacicept uptake if approved. And the FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting sits four days away, with written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22 and the two-day vote on BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon opening Thursday July 23 at White Oak.

Industry

Vera Therapeutics Announces TRUTAKNA (Atacicept-Vymj) Commercial Launch Details Following July 7 FDA Accelerated Approval: $425,000 Per Year List Price for the BAFF/APRIL-Targeting Peptide-and-Fc Fusion Protein, 82 Sales Representatives Deployed at Launch, In-Channel Pharmacy Availability Within Three to Four Weeks, and Ongoing ORIGIN 3 Confirmatory Trial (Blinded Placebo-Controlled eGFR Endpoint) With Results Anticipated in Q3 2026 That Will Determine Whether the Accelerated Approval Converts to Traditional Approval

Vera Therapeutics (NASDAQ: VERA) confirmed commercial-launch parameters for TRUTAKNA (atacicept-vymj) following the July 7, 2026 FDA accelerated approval for adults with primary IgA nephropathy at risk of rapid disease progression. List price: $425,000 per year for the recombinant peptide-and-Fc fusion protein (TACI extracellular domain fused to human IgG1 Fc). Sales force: 82 representatives deployed at launch. Distribution: in-channel pharmacy availability within three to four weeks of approval, with insurance coverage under specialty-pharmacy medical benefit pathways given the subcutaneous injection administration. The July 7 accelerated approval was based on the Phase 3 ORIGIN study 36-week urine protein-to-creatinine ratio (UPCR) endpoint (45.7% reduction versus 6.8% for standard of care). Continued FDA approval may be contingent on verification of clinical benefit in the ongoing ORIGIN 3 confirmatory trial, which continues in a placebo-controlled blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR); results are anticipated in Q3 2026. If the ORIGIN 3 eGFR data hit, TRUTAKNA converts to traditional approval on the harder outcome endpoint.

#vera-therapeutics #trutakna #atacicept #iga-nephropathy #commercial-launch #peptide-fc-fusion #baff #april #origin-3 #list-price
Regulatory

Vertex Pharmaceuticals Povetacicept BAFF/APRIL-Blocking Fusion Protein for Primary IgA Nephropathy Has FDA BLA Acceptance With PDUFA Target Action Date November 30, 2026: Phase 3 Topline Data From March Showed 49.8% Reduction in Urine Protein-Creatinine Ratio at 36 Weeks Versus Placebo; BioSpace Analysis Characterizes the Program as Derisked After the Vera Therapeutics July 7 TRUTAKNA and Novartis July 17 Fabhalta Approvals in the Same Indication

Vertex Pharmaceuticals' (NASDAQ: VRTX) povetacicept, a BAFF/APRIL-blocking fusion protein for primary IgA nephropathy, has US FDA acceptance of its Biologics License Application with a PDUFA target action date of November 30, 2026. Povetacicept works through the same mechanism as Vera Therapeutics' TRUTAKNA (atacicept-vymj), targeting the BAFF and APRIL cytokines that drive plasma-cell antibody production. Phase 3 topline data reported in March 2026 showed a 49.8% reduction in urine protein-creatinine ratio (UPCR) at 36 weeks in povetacicept-treated patients versus placebo (versus 45.7% for TRUTAKNA in the ORIGIN Phase 3). BioSpace analysis published this weekend characterizes the Vertex program as derisked following the Vera TRUTAKNA approval on July 7 and the Novartis Fabhalta traditional approval on July 17 — both marketing campaigns will build IgAN awareness and educate nephrologists on the treatment landscape before povetacicept reaches market, and both approvals validate the FDA's willingness to green-light novel IgAN mechanisms on accelerated pathways. Povetacicept, if approved, would become the first commercialized therapy in Vertex's emerging nephrology franchise.

#vertex-pharmaceuticals #povetacicept #iga-nephropathy #baff #april #peptide-fc-fusion #pdufa #phase-3 #vera-therapeutics #novartis
Regulatory

FDA Pharmacy Compounding Advisory Committee Peptide Meeting Four Days Out (Thursday-Friday July 23-24 at White Oak Campus) With Written-Comment Docket FDA-2025-N-6895 Closing at 11:59 PM ET on Wednesday July 22: Day 1 Reviews BPC-157, KPV, TB-500, and MOTS-c; Day 2 Reviews Emideltide (DSIP), Semax, and Epitalon; FDA Career-Staff Briefing Documents Recommend Against Adding Any of the Seven Peptides to the 503A Bulks List, and Public-Comment Filings by Late-Comment Deadline Will Not Reach Panelists Before the Meeting Opens

The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting sits four days away, with the written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22, 2026. The two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), academic researchers (UC Davis's Paul Knoepfler), and individual physicians and patients across both sides. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.

#pcac #fda #docket #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #peptide-compounding #white-oak